Volatile oil for Wuli cold-dispelling powder, and preparation method, traditional Chinese medicine extract and pharmaceutical preparation thereof
The volatile oil of Wulibahan San is extracted through low-temperature crushing and heating reflux, combined with gas chromatography quality detection, and the problems of unclear dosage and inaccurate drug concentration are solved, which significantly reduces side effects and improves efficacy and safety.
Patent Information
- Application Number
- CN202410898981.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-05
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-07-05
AI Technical Summary
In clinical use, Wulibahansan has problems such as unclear dosage and inaccurate drug concentration, which leads to greater side effects and affects its efficacy and safety.
The volatile oil was extracted by pulverizing caula seeds at low temperature and mixed with green and pepper, and heated and refluxed in water at 4-40℃ to extract the mass ratio and soaking time of the medicinal materials, and mass testing was carried out in combination with gas chromatography to prepare a drug preparation with significantly reduced side effects.
The volatile oil prepared by this method reduces the side effects of the drug, improves its efficacy in dispelling wind and cold, promoting blood circulation and unblocking meridians, and significantly improves the safety of the skin through the optimization of drug preparations.
Smart Images

Figure CN118987098A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of traditional Chinese medicine preparations, and in particular to a Wuli Bahansan volatile oil and a preparation method thereof, a traditional Chinese medicine extract and a pharmaceutical preparation. Background Art
[0002] Wuli Bahansan is made of two medicines, white cauliflower seeds and green pepper, which are crushed and mixed. It has the effects of dispelling wind and cold, activating blood circulation and unblocking collaterals. It can be used for wind-cold, numbness of tendons and bones, sore shoulders and back, back pain and cold legs, eating disorders, stomach cold pain, cold kidney and cold essence, cold uterus, abdominal pain during menstruation, and cold-damp leucorrhea. When using, add egg white and warm water to make a paste, spread it on wax paper, and stick it on the acupuncture points or affected areas. Due to the weak foundation of drug research and vague instructions for use, there are many reports of clinical adverse reactions, and the problem of drug safety needs to be solved urgently. The study found that the unclear clinical dosage and inaccurate drug concentration of Wuli Bahansan are the main causes of clinical adverse reactions of Wuli Bahansan. Therefore, the main pharmacodynamic effects and skin irritation of Wuli Bahansan are taken as the investigation targets, and the preparation process of modern preparations of Wuli Bahansan is established to reduce the occurrence of clinical adverse reactions, which has high clinical application value. Summary of the invention
[0003] Therefore, the technical problem to be solved by the present invention is to overcome the defect of Wuli Bahan San in the prior art that the side effects are large, thereby providing a Wuli Bahan San volatile oil and a preparation method thereof, and a traditional Chinese medicine extract and a pharmaceutical preparation containing the Wuli Bahan San volatile oil.
[0004] To this end, the present invention provides a method for preparing Wuli Bahansan volatile oil, comprising the following steps:
[0005] Step S1: crushing white cauliflower seeds at a temperature below 60° C., and then mixing with the crushed green pepper to obtain a mixed medicinal material;
[0006] Step S2: soak the mixed medicinal materials obtained in step S1 in water at 4-40° C., heat to reflux, and collect the volatile oil of Wuli Bahan Powder.
[0007] The green pepper can be crushed by conventional or ordinary crushing process, or by low temperature crushing process. The white rapeseed can be crushed by low temperature crushing process with the crushing temperature controlled below 60°C.
[0008] Furthermore, in step S2, heating is performed until volatile oil no longer increases; and / or the volume ratio of the mass of the mixed medicinal materials to water is 1 g: 6-10 mL; and / or the soaking time is 1-4 h.
[0009] Furthermore, the mass ratio of the white cauliflower seeds to the green pepper is 100-500:80-400; preferably 500:400.
[0010] Furthermore, in step S1, the rapeseed is crushed at 6-10°C.
[0011] The present invention also provides Wuli Bahan San volatile oil prepared by any of the above-mentioned preparation methods of Wuli Bahan San volatile oil.
[0012] The present invention also provides a Chinese medicine extract, comprising a concentrated solution and Wuli Bahansan volatile oil prepared by any of the above-mentioned methods for preparing Wuli Bahansan volatile oil, wherein the concentrated solution is obtained by collecting and concentrating a water extract while collecting the Wuli Bahansan volatile oil in the preparation process of the Wuli Bahansan volatile oil;
[0013] Preferably, the concentration is carried out by vacuum distillation;
[0014] Preferably, the relative density of the concentrated solution is 0.5 to 20 (60° C.), more preferably 1.0 to 1.2 (60° C.).
[0015] The present invention also provides a pharmaceutical preparation, comprising the Chinese herbal extract and pharmaceutically acceptable excipients; preferably, the pharmaceutical preparation is an ointment or a patch.
[0016] Furthermore, the pharmaceutically acceptable excipients include one or more of an oil phase matrix, an aqueous phase matrix, an emulsifier, and a preservative; preferably, the oil phase matrix is selected from one or more of stearic acid, liquid paraffin, and vaseline; preferably, the preservative is selected from ethyl paraben; preferably, the emulsifier is selected from one or more of Tween 80, stearyl alcohol, and glyceryl monostearate; preferably, the aqueous phase matrix is selected from glycerol.
[0017] The pharmaceutical preparation of the present invention is prepared by conventional processes in the art. For example, glycerol, Tween 80, Span 80, and ethylparaben are mixed, heated, and evenly mixed with the concentrated solution to obtain an aqueous phase. Stearic acid, glyceryl monostearate, liquid paraffin, white vaseline, and octadecyl alcohol are mixed, heated, and an oil phase is obtained. The aqueous phase is then poured into the oil phase while stirring, emulsified, and volatile oil is added to obtain the product.
[0018] The present invention also provides a method for identifying the volatile oil of Wuli Bahan Powder, comprising:
[0019] (1) Preparation of test solution;
[0020] (2) Determine the test solution by gas chromatography or gas chromatography-mass spectrometry using a programmed temperature rise method; the programmed temperature rise method includes: maintaining at 45-55°C for 2.5-3.5 min, increasing to 145-155°C at 4-6°C / min, maintaining for 4-6 min, and then increasing to 245-255°C at 18-22°C / min, and maintaining for 2.5-3.5 min.
[0021] Furthermore, the method for preparing the test solution includes taking the test sample and adding ethyl acetate to dissolve and dilute it to obtain the test solution; preferably, the volume ratio of the test solution to ethyl acetate is 0.1 to 5:25.
[0022] Furthermore, the mass spectrometry conditions in the gas chromatography-mass spectrometry method include: electrospray ionization source (ESI), ion temperature 220-240°C; interface temperature 240-250°C; solvent delay 2-4 minutes; scanning mode SCAN, scanning range m / z 30-450.
[0023] Furthermore, the mass spectrometry conditions in the gas chromatography-mass spectrometry method include: electrospray ionization source (ESI), ion temperature 230°C; interface temperature 250°C; solvent delay 3min; scanning mode SCAN, scanning range m / z 30-450.
[0024] Furthermore, the chromatographic conditions in the gas chromatography or gas chromatography-mass spectrometry also include: injection port temperature 250° C.; carrier gas (He) flow rate 1.0 ml / min; injection volume: 1 μl, no splitting.
[0025] Furthermore, allyl isothiocyanate and butenyl isothiocyanate are used as detection markers.
[0026] Furthermore, when gas chromatography is used, whether peaks appear at retention times of 4.25 min and 4.9 min is used as the basis for detection. If peaks appear at retention times of 4.25 min and 4.9 min, it indicates that the quality is qualified, otherwise it is unqualified.
[0027] Furthermore, when gas chromatography-mass spectrometry is used, a mass-to-charge ratio of 87 m / z is used as the characteristic fragment of the propylene isothiocyanate, and a mass-to-charge ratio of 101 m / z is used as the characteristic fragment of the butenyl isothiocyanate.
[0028] The technical solution of the present invention has the following advantages:
[0029] 1. The preparation method of Wuli Bahan Powder volatile oil provided by the present invention comprises the following steps: step S1: taking white cauliflower seeds, crushing them at a temperature below 60°C, and mixing them with the crushed green pepper to obtain a mixed medicinal material; step S2: taking the mixed medicinal material obtained in step S1 and soaking it in water at 4-40°C, heating and refluxing it, and collecting Wuli Bahan Powder volatile oil; the Wuli Bahan Powder volatile oil obtained by crushing the white cauliflower seeds at a low temperature (below 60°C) and soaking and extracting them at 4-40°C (normal temperature) before heating and refluxing them has obvious differences in chemical composition from the volatile oil obtained by un-crushed or conventionally crushed samples or directly high-temperature treatment, and the side effects of the prepared pharmaceutical preparation are significantly reduced, and at the same time, it has good therapeutic effects of dispelling wind and cold, promoting blood circulation and unblocking collaterals. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0031] Figure 1 It is a GC-MS TIC comparison chart of sample 1 and sample 2 in Example 1; from top to bottom, it is sample 2 and sample 1;
[0032] Figure 2 It is a GC-MS TIC comparison chart of sample 1 and sample 3 in Example 1; from top to bottom, it is sample 3 and sample 1;
[0033] Figure 3 is a GC-MS TIC comparison chart of sample 4 in Example 1;
[0034] Figure 4 This is the mass spectrum of the component with retention time 4.25min in sample 1;
[0035] Figure 5 It is the database matching mass spectrum of retention time 4.25min;
[0036] Figure 6 This is the mass spectrum of the component with retention time 4.9min of sample 1;
[0037] Figure 7 It is the database matching mass spectrum of retention time 4.9min;
[0038] Figure 8 These are HE staining pictures of rats in different groups in Example 2. DETAILED DESCRIPTION
[0039] The following examples are provided for a better understanding of the present invention, but are not intended to limit the best mode of implementation, nor to limit the content and protection scope of the present invention. Any product identical or similar to the present invention obtained by anyone under the inspiration of the present invention or by combining the features of the present invention with other prior arts shall fall within the protection scope of the present invention.
[0040] If no specific experimental steps or conditions are specified in the examples, the conventional experimental steps or conditions described in the literature in the field can be used. If no manufacturer is specified for the reagents or instruments used, they are all conventional reagent products that can be obtained commercially.
[0041] Example 1 Study on the preparation process of Wulibahansan
[0042] 1. Instruments / Equipment
[0043]
[0044] 2. Reagents
[0045]
[0046] 3. Medicinal materials
[0047]
[0048] 4. Experimental Methods
[0049] 4.1 Sample preparation
[0050] 4.1.1 Low temperature crushing-cold soaking-reflux extraction
[0051] Take the pure medicinal material of white flower cauliflower seeds, use a refrigeration grinder to grind at a temperature of 10°C, take 200g of the ground white flower cauliflower seeds and add them into a 5000mL round-bottom flask. Take green pepper, grind it with a conventional grinder, take 160g of the ground green pepper and add it into the above round-bottom flask to obtain a mixed medicinal material; add 3200mL of room temperature (temperature is 25°C) water to the mixed medicinal material, soak for 2h, heat and reflux for 6h (volatile oil no longer increases), and collect the volatile oil of Wuli Bahan Powder (recorded as sample 1).
[0052] 4.1.2 Low temperature crushing-reflux extraction
[0053] Take the pure medicinal material of white cauliflower seeds and use a refrigeration grinder to low-temperature grind at a temperature of 10°C. Take green pepper and grind it with a conventional grinder. Take 200g of the white cauliflower seeds after the above low-temperature grinding and 160g of the green pepper after conventional grinding to obtain a mixed medicinal material. Add 3200mL of room temperature (temperature is 25°C) water to a round-bottom flask and boil it, add the mixed medicinal material in step S1, heat and reflux for 6h (volatile oil no longer increases), and collect the volatile oil of Wuli Bahan Powder (recorded as sample 2).
[0054] 4.1.3 Raw material-cold water-reflux extraction
[0055] Take green peppercorns, grind them with a conventional grinder, take 200g of un-crushed white flower seed medicinal material and 160g of conventionally crushed green peppercorns to obtain a mixed medicinal material. Add 3200mL of room temperature (temperature is 25°C) water to the mixed medicinal material, directly heat and reflux for 6h (volatile oil no longer increases), and collect the volatile oil of Wuli Bahan Powder (recorded as sample 3).
[0056] 4.1.4 Low-temperature crushing-cold soaking-reflux extraction of rapeseed
[0057] Take the pure medicinal material of white flower cauliflower seeds, use a refrigeration grinder to perform low-temperature grinding at a temperature of 10°C, take 200g of the white flower cauliflower seeds after the above low-temperature grinding and add them into a 5000mL round-bottom flask. Add 3200mL of room temperature (temperature is 25°C) water, soak for 2h, and then heat and reflux for 6h (volatile oil no longer increases), and collect the volatile oil of Wuli Bahan Powder (recorded as sample 4).
[0058] 4.2 Volatile oil quality testing method
[0059] The quality of samples 1-4 was tested according to the following methods.
[0060] Preparation of the test solution: Take 0.1 mL of the collected volatile oil sample, place it in a 25 mL volumetric flask, add ethyl acetate to dissolve and dilute to the mark to obtain the test solution;
[0061] The test solution was detected by gas chromatography-mass spectrometry (GC-MS), and the chromatographic conditions were as follows: Agilent HP5MS chromatographic column (30m×0.25mm, 0.25μm); programmed temperature: 50℃ for 3min, increased to 150℃ at 5℃ / min, maintained for 5min, then increased to 250℃ at 20℃ / min, maintained for 3min; injection port temperature 250℃; carrier gas (He) flow rate 1.0ml / min; injection volume: 1μl, no splitting.
[0062] The mass spectrometry conditions were as follows: electrospray ionization source (ESI), ion temperature 230°C; interface temperature 250°C; solvent delay 3 min; scanning mode SCAN, scanning range m / z 30-450.
[0063] 5. Experimental Results
[0064] 5.1 Comparison of volatile oil components obtained by different treatment methods
[0065] The TIC comparison chart of each group is shown in Figure 1-3 As shown in the figure, compared with samples 2 and 3, the GC-MS TIC graphs of the volatile oils of samples 1 and 4 have certain differences in composition. Among them, the three chromatographic peaks with retention times of 4.25min, 4.9min, and 19.0min appear regularly in the GC-MS TIC graphs of samples 1 and 4, but not in samples 2 and 3. Among them, the component with retention time 4.25min is allyl isothiocyanate (see Figure 4 , 5 ); retention time 4.9min component is butenyl isothiocyanate (see Figure 6 , 7 ).
[0066] Therefore, the mass-to-charge ratio of 87 m / z as the characteristic fragment of propylene isothiocyanate and the mass-to-charge ratio of 101 m / z as the characteristic fragment of butyl isothiocyanate can be used to detect the quality of Wuli Bahan San volatile oil and pharmaceutical preparations containing Wuli Bahan San volatile oil.
[0067] 5.2 Confirmation of the preparation method of the improved new drug patch of Wuli Bahansan
[0068] From the GC-MS comparative analysis, it can be seen that the chemical composition of the Wuli Bahan Powder volatile oil obtained by low-temperature crushing of white flower seeds and mixing them with crushed green peppercorns, then soaking them at low temperature and then heating and reflux extraction is significantly different from that of the Wuli Bahan Powder volatile oil obtained by not crushing the white flower seeds or directly subjecting them to high-temperature treatment (conventional crushing or direct heating and reflux), in which allyl isothiocyanate and butenyl isothiocyanate are destroyed.
[0069] In traditional Chinese medicine, both white cauliflower seeds and white mustard seeds can be used as foaming ointments for clinical use. The drugs are crushed and mixed with solvents and then fixed to the acupuncture points with adhesive tape, causing the acupuncture points to "foam". The preparation, operation and mechanism of action of modern "foaming ointments" are similar to the "foaming" of traditional Chinese clinical moxibustion (References: He Hongju, Chen Hang, SCHNITZLERW H. Identification and content analysis of glucosinolates in Brassica vegetables [J]. Chinese Agricultural Science, 2002, 35(2): 192-197; Bell L, OLOYEDE OO, LIGNOU S, et al. Taste and flavor perceptions of glucosinolates, isothiocyanates, and related compounds [J]. Molecular Nutrition Food Research, 2018, 62(18): 1-13. DOI: 10.1002 / mnfr.201700990.). Some of the modes of action of Tianjiu blistering therapy are similar to acupuncture therapy, which belongs to body surface stimulation therapy and may have some common mechanisms of action, namely, the use of irritating drugs to dilate local skin capillaries, causing "redness, swelling, heat, and pain" reactions, local congestion, subepidermal exudation, infiltration of local inflammatory factors, enhanced local microcirculation of the skin, obvious skin edema, and blister formation, involving a sterile inflammatory reaction with inflammatory cell infiltration in the skin surface structure (Reference: MITHEN RF. Glucosinolates and their degradation products [J]. Advances in Botanical Research, 2001, 35: 214-250. DOI: 10.1016 / s0065-2296 (01) 35008-5.). Some studies have suggested that neuro-endocrine-immune regulation may be one of their basic modes of action (Reference: Tian Yan, Deng Fangming, Qing Zhixing, Zhao Lingyan, Peng Pei. Research progress on the structure and function of glucosinolates in cruciferous plants [J]. Food Science, 2020, 41(01): 292-303.).Studies have shown that isothiocyanate compounds and sinapinic acid thiocyanate can produce a "meridian-viscera-related" effect by activating TRPA1 channels (References: Akram Waheed, Saeed Taiba, Ahmad Aqeel, Yasin Nasim A, Akbar Muhammad, Khan Waheed U, Ahmed Shakeel, Guo Juxian, Luo Wenlong, Wu Tingquan, Li Guihua. Liquiritin elicitation can increase the content of medicinally important glucosinolates and phenolic compounds in Chinese kale plants. [J]; Journal of the science of food and agriculture, 2020, 100 (4). [5]. Franziska S. Hanschen. Domestic boiling and salad preparation habits affect glucosinolated evolution in red cabbage (Brassica oleracea var. cabitata f.rubra)[J].FoodChemistry,2020,321(prepublish).).
[0070] Propylene isothiocyanate and butenyl isothiocyanate are the main active ingredients of the topical patch of the present invention. In order to increase the content of the active ingredient, the proposed preparation method of the volatile oil of Wulibahansan is to take the white flower vegetable seed pure medicinal material, crush it at a low temperature below 60°C (for example, 10°C), mix it with the crushed green pepper medicinal material, add 6 to 10 times the volume of water, soak it in water at 4 to 40°C for 1 to 4 hours, heat and reflux until the volatile oil no longer increases, and collect the volatile oil.
[0071] In addition, it can be shown that the above GC-MS method can also be used to detect the quality of the Wuli Bahansan volatile oil prepared by the present invention.
[0072] Example 2 Study on the irritating components of Wulibahansan
[0073] 1. Instruments and test drugs
[0074] 1.1 Experimental drugs
[0075] Preparation of drug 1: Wuli Bahansan Chinese patent medicine, national medicine standard Z11020568, Beijing Tongrentang Co., Ltd. Tongrentang Pharmaceutical Factory, batch number 21101027. Mix 10ml warm water, 5ml egg white, and 3g Wuli Bahansan Chinese patent medicine, spread on wax paper to prepare a patch, the raw drug amount per unit area of the patch is: 0.013g / cm 2 .
[0076] Preparation of test drug 2: Take the pure medicinal material of white flower cauliflower seeds, use a refrigeration grinder to grind at a temperature of 10°C, take 500g of the ground white flower cauliflower seeds and add them into a round-bottom flask. Take green pepper, grind it with a conventional grinder, take 400g of the ground green pepper and add it into the above round-bottom flask to obtain a mixed medicinal material; add 7200mL of room temperature (temperature is 25°C) water to the mixed medicinal material, soak for 2h, heat and reflux for 6h (volatile oil no longer increases), collect the volatile oil to obtain the volatile oil part of the crushed medicinal material of Wuli Bahansan, refrigerate for use, collect the extract, and recover the solvent under reduced pressure at 70°C to obtain a concentrated solution (relative density at 60°C is 1.0).
[0077] 8.0g glycerol, 3.0g Tween 80, 0.5g Span 80, 0.06g ethylparaben were mixed and heated to 75-80°C, and then mixed evenly with 50g (based on the amount of crude drugs) Wulibahansan concentrate (i.e. 5.6wt% of the concentrate prepared above) to prepare the water phase. 2.0g stearic acid, 6.0g glyceryl monostearate, 4.0g liquid paraffin, 2.0g white vaseline, and 4.0g octadecyl alcohol were mixed and heated to 75-80°C to prepare the oil phase. Then pour the aqueous phase into the oil phase while stirring, emulsify at 300 rpm for 15 min (80°C), continue stirring, and when the temperature drops to about 40°C, add 50 g (in terms of crude drug amount) of Wuli Bahansan volatile oil (i.e. 5.6 wt% of the volatile oil prepared above), continue stirring until cooled to obtain Wuli Bahansan ointment, spread on wax paper to obtain a patch, the crude drug amount per unit area of the patch is: 0.013 g / cm 2 .
[0078] 1.2. Experimental animals
[0079] Breed and strain: Wistar rats. Grade: SPF grade animals. Male. Age: about 4-5 weeks old. Average animal weight: 160g. Animal source: Beijing Huafukang Biotechnology Co., Ltd. Certificate No.: SCXK (Beijing) 2019-0008.
[0080] 1.3 Experimental instruments
[0081]
[0082]
[0083] 2. Experimental Methods
[0084] Experimental design: Wistar rats were adaptively fed for 7 days. All rats were depilated on their abdomens one day before administration and divided into 3 groups, 5 rats in each group, namely, a blank group, a commercial drug group, and a drug administration group of the present invention. Among them, the abdomen of the blank group was wrapped with tape, and no drug was added. The commercial drug group and the drug administration group of the present invention were given the same area of patches corresponding to the test drug 1 and the test drug 2 on the depilated area of the rats (the patch area was: 16 cm 2 (4cm*4cm), wrap with medical tape to prevent tearing. Administer once every other day, apply for 4 hours each time, and continue to administer for 20 days.
[0085] Detection: The rats were killed on the 22nd day of administration, and the skin was fixed and HE staining and pathological examination were performed later. The samples sent for examination were fixed with 4% paraformaldehyde. After the fixation was in good condition, they were trimmed, dehydrated, embedded, sliced, stained, and sealed in strict accordance with the SOP procedures of the pathological laboratory test of this unit. The qualified samples were finally examined under the microscope.
[0086] Browse the slices under a microscope or browse digital slices, observe the tissue slices in detail at different magnifications, describe the basic pathological changes in the slices, such as congestion, congestion, hemorrhage, edema, degeneration, necrosis, hyperplasia, fibrosis, organization, granulation tissue, inflammatory changes, etc., and reflect the differences between the slices. Image the typical lesions and mark them with arrows in the word document.
[0087] 3. Experimental results
[0088] like Figure 8 As shown in the data, the epidermis of the rats in the blank group had an intact structure, the squamous epithelial cells had normal morphology and structure and were tightly arranged, the dermis was rich in collagen fibers, and accessory organs such as hair follicles and sebaceous glands were visible, the subcutaneous muscle layer had an intact structure and uniform thickness, the muscle fibers had normal morphology and structure and were regularly arranged, and no obvious inflammation was observed.
[0089] In the skin tissue of the rats in the commercially available drug group, slight thickening of the epidermis (black arrow) was observed locally; slight connective tissue hyperplasia (yellow arrow) was observed in the dermis, accompanied by punctate infiltration of lymphocytes (red arrow).
[0090] In the skin tissue of the drug administration group of the present invention, mild thickening of the epidermis layer can be seen locally (black arrow); lymphocyte punctate infiltration can be seen in the local dermis layer (yellow arrow). Compared with the commercially available drug group, the inflammatory response of the skin pathological examination of the rats in the drug administration group of the present invention was significantly reduced, indicating that the drug of the present invention has low irritation and can significantly improve the side effects on the skin.
[0091] Example 3: Experimental study on the efficacy of Wulibahansan
[0092] 1. Experimental Animals
[0093] Species and strain: Wistar; Gender: female; Animal grade: SPF; Weight: 190-200g; Animal source: Sibefor (Beijing) Biotechnology Co., Ltd.; Animal certificate number: 110324231105457587; Experimental unit use license number: SYXK (Beijing) 2023-0004.
[0094] 2. Experimental samples, reagents, instruments and equipment information
[0095] 2.1 Sample Information
[0096] Preparation of drug 1: Wuli Bahansan Chinese patent medicine, national medicine standard Z11020568, Beijing Tongrentang Co., Ltd. Tongrentang Pharmaceutical Factory, batch number 21101027. Take 10ml warm water, 5ml egg white, and 6g Wuli Bahansan Chinese patent medicine, mix them, spread them on wax paper, and prepare a patch. The raw drug amount per unit area of the patch is: 0.026g / cm 2 , recorded as test drug 1. Prepare freshly before daily use.
[0097] Preparation of reagent 2: same as reagent 2 in Example 2.
[0098] 2.2 Device Information
[0099] YLS-7C toe solvent measuring instrument, model: YLS-7C, manufacturer: Jinan Yiyan Technology Development Co., Ltd.
[0100] 3 Experimental methods
[0101] 3.1 Model Method
[0102] Rats were randomly divided into a blank control group and a model group. Before modeling, the left hind foot pad of the rat was disinfected with alcohol, and 0.05 ml of Freund's complete adjuvant (CFA, brand: chondrex, number: 7027, 10 mg / ml) was intradermally injected. After half of the needle was injected forward, the needle was turned to inject all the CFA. After the needle was pulled out, it was pressed for a certain time to prevent overflow to construct an arthritis model group. One week after the injection, rats without disease were screened out as required (foot swelling ≤ the highest value of the normal group). The blank control group was injected with an equal amount of saline at the same time. The arthritis model group was randomly divided into 5 groups, including a model group, a low-dose group of Wuli Bahansan Chinese patent medicine group, a high-dose group of Wuli Bahansan Chinese patent medicine group, a Wuli Bahansan ointment group of the present invention, and a positive drug dexamethasone group. There were at least 7 rats in each group.
[0103] 3.2 Grouped drug administration method
[0104] The Wuli Bahan Powder Chinese patent medicine group and the Wuli Bahan Powder paste group of the present invention took the patches corresponding to the test drug 1 and the test drug 2 respectively, and applied the patches to the feet and abdomen of the rats with gauze to fix them. The total application area of the drugs in the patches was: 16 cm 2 (4cm*4cm), once a day, each time the patch was fixed for 4 hours, and the drug was administered continuously for 16 days. Positive drug dexamethasone group: continuous intragastric administration of dexamethasone solution for 16 days, once a day, each dose was 0.3mg / kg. The blank control group and the model group were gavaged with 0.3mg / kg of purified water in parallel.
[0105] Behavioral observation: The body weight and toe volume of rats were measured one day before injection, which was regarded as the baseline. Thereafter, the body weight and toe volume were measured every week, and the toe volume was measured by water replacement method until the last measurement before sampling.
[0106] 3.3 Effect of Wulibahansan on plantar volume in rat arthritis model
[0107] The volume of the right hind foot (secondary lesion side) of the rats was measured once before modeling, before drug administration, and on the 7th and 14th days of drug administration. The measurement range was the ankle joint and below. The test results are as follows.
[0108]
[0109] Note: Comparison between model group and control group, *p<0.05, **p<0.01 (control group n=9, other groups n=7)
[0110] The other groups were compared with the model group, #p<0.05.##p<0.01
[0111] As can be seen from the above table, the right hind foot of the rats was obviously swollen after modeling, and there was a significant difference between the model group and the control group. After 7 days of administration, the swelling of the right hind foot of the rats in the positive drug group was significantly reduced, which was significantly different from the model group; the swelling of the right hind foot of the rats in the Wuli Bahansan ointment group of the present invention showed a certain trend of reduction, and there was no significant difference compared with the model group; the swelling of the right hind foot of the rats in the Wuli Bahansan Chinese patent medicine group showed no obvious trend of reduction.
[0112] After 14 days of administration, the swelling of the right hind foot of the rats in the positive drug group was significantly reduced, which was significantly different from that in the model group; the swelling of the right hind foot of the rats in the Wuli Bahansan ointment group of the present invention was significantly reduced, which was significantly different from that in the model group.
[0113] 4. Conclusion
[0114] The Wuli Bahansan Chinese patent medicine group and the Wuli Bahansan ointment group of the present invention have good therapeutic effects on plantar volume swelling in arthritis rats with Freund's complete adjuvant, and the effect of Wuli Bahansan ointment is better than that of Wuli Bahansan Chinese patent medicine.
[0115] Obviously, the above embodiments are merely examples for the purpose of clear explanation, and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived therefrom are still within the scope of protection of the invention.
Claims
1. A method for preparing Wuli Bahansan volatile oil, characterized in that: The steps include: Step S1: crushing white cauliflower seeds at a temperature below 60° C., and then mixing with the crushed green pepper to obtain a mixed medicinal material; Step S2: soak the mixed medicinal materials obtained in step S1 in water at 4-40° C., heat to reflux, and collect the volatile oil of Wuli Bahan Powder.
2. The method for preparing the Wuli Bahansan volatile oil according to claim 1, characterized in that: In step S2, heating is performed until the volatile oil no longer increases; and / or the mass ratio of the mixed medicinal materials to the volume of water is 1 g: 6 to 10 mL; and / or the soaking time is 1 to 4 h.
3. The method for preparing the Wuli Bahansan volatile oil according to claim 1 or 2, characterized in that: The mass ratio of the white cauliflower seeds to the green pepper is 100-500:80-400, preferably 500:
400.
4. The method for preparing the Wuli Bahansan volatile oil according to any one of claims 1 to 3, characterized in that: In step S1, the cauliflower seeds are crushed at 6-10°C.
5. Wuli Bahan San volatile oil obtained by the preparation method of Wuli Bahan San volatile oil according to any one of claims 1 to 4.
6. A Chinese medicine extract, characterized in that: A concentrated liquid and Wuli Bahansan volatile oil prepared by the preparation method of Wuli Bahansan volatile oil according to any one of claims 1 to 4, wherein the concentrated liquid is obtained by collecting and concentrating a water extract while collecting the Wuli Bahansan volatile oil in the preparation process of the Wuli Bahansan volatile oil; Preferably, the concentration is carried out by vacuum distillation; Preferably, the relative density of the concentrated solution is 0.5 to 20, more preferably 1.0 to 1.
2.
7. A pharmaceutical preparation, characterized in that The Chinese medicinal extract according to claim 6 also includes pharmaceutically acceptable excipients; preferably, the pharmaceutical preparation is an ointment or a patch.
8. The pharmaceutical preparation according to claim 7, characterized in that The pharmaceutically acceptable excipients include one or more of an oil phase matrix, an aqueous phase matrix, an emulsifier, and a preservative; preferably, the oil phase matrix is selected from one or more of stearic acid, liquid paraffin, and vaseline; preferably, the preservative is selected from ethyl paraben; preferably, the emulsifier is selected from one or more of Tween 80, Span 80, octadecyl alcohol, and glyceryl monostearate; preferably, the aqueous phase matrix is selected from glycerol.
9. A quality testing method for the Wuli Bahansan volatile oil according to claim 5, characterized in that: include: (1) Preparation of test solution; (2) Determine the test solution by gas chromatography or gas chromatography-mass spectrometry using programmed temperature; The programmed temperature rising method includes: maintaining at 45-55°C for 2.5-3.5 minutes, increasing to 145-155°C at 4-6°C / min, maintaining for 4-6 minutes, and then increasing to 245-255°C at 18-22°C / min, maintaining for 2.5-3.5 minutes.
10. The quality detection method of Wuli Bahansan volatile oil according to claim 9, characterized in that: The preparation method of the test solution comprises: taking the test sample and adding ethyl acetate to dissolve and dilute it, so as to obtain the test solution; preferably, the volume ratio of the test solution to ethyl acetate is 0.1 to 5:25.
Citation Information
Patent Citations
Spiderflower seed oil suppository and preparation method thereof
CN104382967A
Method for quality detection of Wuli cold dispelling powder
CN105738556A
